StockTipsArenaBeta

BUY Shilpa Medicare Limited — Rajesh Agarwal, AUM Capital

BUYShilpa Medicare Limited

byRajesh Agarwal, AUM CapitalHorizon: 1 year31 Aug 2026via NDTV Profit

Entry₹947.95Inferred
Target₹1,100
Total upside +16.04%
Stop lossNot given
CMP₹961.15Just now
Active+1.39%+14.45%upside left 12 mo left
Follow Rajesh Agarwal for new callsGet alertsWatch SHILPAMED for new buy/sell callsGet alertsSee 1 other Long-term pick this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 14 Sept, 4:02 pm IST
7 supporting7 neutral3 opposing
Supports the BUY call (7)

Shilpa Medicare gets final approval for 5-day chemotherapy anti-nausea injection

NewsCnbc-Tv18·11 Sept · 3d ago

(opens in new tab)

Shilpa Medicare's novel injectable OERIS (Ondansetron Extended-Release Injection, 100 mg/mL) has received final approval from the Subject Expert Committee (SEC) for marketing.

BSE · Company Update·11 Sept · 3d ago

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·11 Sept · 3d ago

Neutral / worth noting (7)

Shilpa Medicare recalls 27,923 chemotherapy drug vials in US over discolouration

NewsCnbc-Tv18·18 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (3)

Shilpa Medicare Limited Initiates Recall of Pemrydi Rtu (Pemetrexed Injection) Due to Discolored Solution

NewsGoogle News·29 Aug · 2w ago

(opens in new tab)

Shilpa Medicare Recalls Over 27,000 Chemotherapy Vials In US After Discolouration Reports

NewsNdtv-Profit·18 Aug · 4w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.